<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/cs.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [];
		
	</script>
</head>
<body class="popup-2-1">
<div id="popup"> 
<img src="images/cs-01-popup-01-chart.jpg" width="789" height="387" alt="Baseline Values"> 
<div class="copy1">ATV/RTV, atazanavir/ritonavir; KALETRA, lopinavir/ritonavir; TDF, tenofovir; FTC, emtricitabine. Patients taking KALETRA were able to switch<br>from the soft-gel capsule to the tablet formulation after 48 weeks. 39 patients switched to tablets between weeks 48 and 96.</div>
</div>

</body>

</html>